We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

60 hedge funds and large institutions have $32.8M invested in TScan Therapeutics in 2026 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $30.7M → $32.8M (+$2.13M)

3.27% more ownership

Funds ownership: 58.5% → 61.77% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2% less funds holding

Funds holding: 61 → 60 (-1)

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
0.74%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
11
Increased
15
Reduced
20
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.13M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$663K
3
Two Sigma Investments
Two Sigma Investments
New York
+$596K
4
BI
BVF Inc
California
+$361K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$267K

Top Sellers

Rank Fund Capital Flow
1
Aberdeen Group
Aberdeen Group
United Kingdom
-$927K
2
Jane Street
Jane Street
New York
-$261K
3
XT
XTX Topco
Cayman Islands
-$169K
4
Marshall Wace
Marshall Wace
United Kingdom
-$109K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$62.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
51
Osaic Holdings
Arizona
$9.85K -$2.66K -2,489 -20%
TRCT
52
Tower Research Capital (TRC)
New York
$5.11K -$1.82K -1,703 -25%
Federated Hermes
53
Federated Hermes
Pennsylvania
$4.34K -$742 -694 -14%
Fidelity Investments
54
Fidelity Investments
Massachusetts
$1.31K +$855 +800 +160%
BNP Paribas Financial Markets
55
BNP Paribas Financial Markets
France
$720 -$27.4K -25,647 -97%
SS
56
SBI Securities
Japan
$396 – – –
SWP
57
Strategic Wealth Partners
Ohio
$314 – – –
CIAM
58
Caitong International Asset Management
Hong Kong
$2 +$2 +2 New
Citigroup
59
Citigroup
New York
$1 +$1 +1 New
Two Sigma Advisers
60
Two Sigma Advisers
New York
– -$354K -353,900 Closed
TCM
61
Tang Capital Management
California
– -$46.1K -46,131 Closed
HF
62
HRT Financial
New York
– -$26K -26,581 Closed
Neuberger Berman Group
63
Neuberger Berman Group
New York
– -$18.4K -18,400 Closed
RS
64
R Squared
Hong Kong
– -$16K -16,033 Closed
TSS
65
Two Sigma Securities
New York
– -$15.9K -15,942 Closed
Point72 Asset Management
66
Point72 Asset Management
Connecticut
– -$14.5K -14,512 Closed
MSU
67
Mizuho Securities USA
New York
– -$10.1K -10,000 Closed
WPW
68
Waldron Private Wealth
Pennsylvania
– -$10K -10,000 Closed
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
– -$322 -301 -80%
Rockefeller Capital Management
70
Rockefeller Capital Management
New York
– -$200 -200 Closed
Northwestern Mutual Wealth Management
71
Northwestern Mutual Wealth Management
Wisconsin
– -$8 -8 Closed
1 2
3

TCRX Hedge Fund Activity: Q1 2026 in Review

60 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2026, worth a combined $32.8M — up 6.9% from $30.7M a quarter earlier.

Fund positioning in TCRX was balanced in Q1 2026: 11 funds opened new positions, 11 closed out, 15 added to existing stakes and 20 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.13M. The largest seller was Aberdeen Group, cutting an estimated $927K.

  • 60 institutional investors held TScan Therapeutics (TCRX) as of Q1 2026, down from 61 in Q4 2025.
  • Funds reported $32.8M of TScan Therapeutics stock for Q1 2026, up 6.9% quarter-over-quarter.
  • 11 funds opened new TScan Therapeutics positions in Q1 2026 and 11 closed out, a net change of 0 holders.
  • The largest TScan Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $1.13M added.
  • The largest TScan Therapeutics seller in Q1 2026 was Aberdeen Group, an estimated $927K sold.

Based on aggregated 13F filings for Q1 2026.